NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Thank you Nick119, i was glad to see the slide below because Dr. Linda Liau basically telegraphed and laid out how the the DCVax-L clinical trial data, and revised Primary Endpoint in the revised SAP will be analyzed.

According to the revised SAP, the new Primary Endpoint is as follows:

compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma. This endpoint will be assessed using 3 different analyses

Because of Dr. Liau's slide tonight, now we know what the 3 different analyses are:

Analysis 1: Cox Proportional Harzards

Analysis 2: Conditional Survival

Analysis 3: Subgroups, Cox PH